Therefore, these results indicate that ICI treatment rather than chemotherapy or target therapy may be more suitable for endometrial carcinoma, colorectal adenocarcinoma, and stomach adenocarcinoma patients with SETD2 mutations. The gene discussed is SETD2; the disease is gastric adenocarcinoma.